^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MDC-CAR-BCMA001
i
Other names: MDC-CAR-BCMA001
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Dresden University of Technology, German Cancer Research Center
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
3ms
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Recruiting, Technische Universität Dresden | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
Trial completion date • Trial primary completion date
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
MDC-CAR-BCMA001
almost2years
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Recruiting, Technische Universität Dresden | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
CD38 positive
|
MDC-CAR-BCMA001
2years
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Technische Universität Dresden | Initiation date: Jul 2023 --> Dec 2023
Trial initiation date • CAR T-Cell Therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
CD38 positive
|
MDC-CAR-BCMA001
over2years
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Technische Universität Dresden
New P1 trial • CAR T-Cell Therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
CD38 positive
|
MDC-CAR-BCMA001
Share via
